Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improved Potency of Hyperactive and Actin-resistant Human DNase I Variants for Treatment of Cystic Fibrosis and Systemic Lupus Erythematosus

1 Jul 1998

Abstract excerpt

The ability of recombinant human DNase I (DNase I) to degrade DNA to lower molecular weight fragments is the basis for its therapeutic use in cystic fibrosis (CF) patients and its potential use as a treatment for systemic lupus erythematosus (SLE). To increase the potency of human DNase I, we have generated and characterized three classes of mutants: (a) hyperactive variants, which have from one to six additional...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced biosensing and bioanalysis techniques
Share to CRISPR and Genetic Engineering
Share to Cystic Fibrosis Research Advances

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 9660804
DOI: 10.1074/jbc.273.29.18374

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improved Potency of Hyperactive and Actin-resistant Human DNase I Variants for Treatment of Cystic Fibrosis and Systemic Lupus ErythematosusPMID 9660804Read ↗

Actin-Resistant DNase1L2 as a Potential Therapeutics for CF Lung DiseaseSemantic proximity Read ↗

Hyperactivity of Human DNase I VariantsSemantic proximity Read ↗

The Structure of Human DNase I Bound to Magnesium and Phosphate Ions Points to a Catalytic Mechanism Common to Members of the DNase I-like SuperfamilySemantic proximity Read ↗

Breaking Bad: Exploring & Complementing the Effects of the DNASE1L3 p.Arg206Cys Variant on Cell-Free DNA from an Isogenic Cell Line ModelSemantic proximity Read ↗

Human and Extracellular DNA Depletion for Metagenomic Analysis of Complex Clinical Infection Samples Yields Optimized Viable Microbiome ProfilesSemantic proximity Read ↗

Plasma DNA Profile Associated with DNASE1L3 Gene Mutations: Clinical Observations, Relationships to Nuclease Substrate Preference, and In Vivo Correction.Semantic proximity Read ↗

A secretory leukocyte protease inhibitor variant with improved activity against lung infection.Semantic proximity Read ↗

DNA-PKcs Inhibition Improves Sequential Gene Insertion of the Full-Length <i>CFTR</i> cDNA in Airway Stem CellsSemantic proximity Read ↗

DNA-PKcs inhibition improves sequential gene insertion of the full-length CFTR cDNA in airway stem cellsSemantic proximity Read ↗

Heavy and Light Chain Variable Single Domains of an Anti-DNA Binding Antibody Hydrolyze Both Double- and Single-stranded DNAs without Sequence SpecificitySemantic proximity Read ↗

Bioengineering: alpha 1-proteinase inhibitor site-specific mutagenesis. The prospect for improving the inhibitor.Semantic proximity Read ↗

Application of directed evolution and back-to-consensus algorithms to human alpha1-antitrypsin leads to diminished anti-protease activity and augmented anti-inflammatory activities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.